Computational analysis of molecular basis of 1:1 interactions of NRG-1β wild-type and variants with ErbB3 and ErbB4

被引:21
|
作者
Luo, C
Xu, LF
Zheng, SX
Luo, Z
Jiang, XM
Shen, JH
Jiang, HL
Liu, XF
Zhou, MD
机构
[1] Shanghai Inst Biol Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Ctr Drug Discovery & Design, Shanghai 201203, Peoples R China
[2] Chinese Acad Sci, Grad Sch, Shanghai, Peoples R China
[3] Zensun Shanghai Sci & Technol Ltd, Shanghai, Peoples R China
[4] E China Univ Sci & Technol, Sch Pharm, Shanghai 200237, Peoples R China
关键词
EGFR; NRG-1; beta; ErbB; ligand-protein interactions; binding free energy; molecular dynamics; MM-PBSA;
D O I
10.1002/prot.20443
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The neuregulin/ErbB system is a growth factor/receptor cascade that has been proven to be essential in the development of the heart and the sympathetic nervous system. However, the basis of the specificity of ligand-receptor recognition remains to be elucidated. In this study, the structures of NRG-1 beta/ErbB3 and NRG-1 beta/ErbB4 complexes were modeled based on the available structures of the homologous proteins. The binding free energies of NRG-1 beta to ErbB3 and ErbB4 were calculated using the molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) computational method. In addition, computational alanine-scanning mutagenesis was performed in the binding site of NRG-1 beta and the difference in the binding free energies between NRG-1 beta mutants and the receptors was calculated. The results specify the contribution of each residue at the interaction interfaces to the binding affinity of NRG-1 beta with ErbB3 and ErbB4, identifying several important interaction residue pairs that are in agreement with previously acquired experimental data. This indicates that the presented structural models of NRG-1 beta/ErbB3 and NRG-1 beta/ErbB4 complexes are reliable and could be used to guide future studies, such as performing desirable mutations on NRG-1 beta to increase the binding affinity and selectivity to the receptor and discovering new therapeutic agents for the treatment of heart failure. (c) 2005 Wiley-Liss, Inc.
引用
收藏
页码:742 / 756
页数:15
相关论文
共 50 条
  • [31] Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1
    Hutcheson, Iain R.
    Goddard, Lindy
    Barrow, Denise
    McClelland, Richard A.
    Francies, Hayley E.
    Knowlden, Janice M.
    Nicholson, Robert I.
    Gee, Julia M. W.
    BREAST CANCER RESEARCH, 2011, 13 (02):
  • [32] STAT5b is a key effector of NRG-1/ERBB4-mediated myocardial growth
    Vaparanta, Katri
    Jokilammi, Anne
    Paatero, Ilkka
    Merilahti, Johannes A.
    Heliste, Juho
    Hemanthakumar, Karthik Amudhala
    Kivela, Riikka
    Alitalo, Kari
    Taimen, Pekka
    Elenius, Klaus
    EMBO REPORTS, 2023, 24 (05)
  • [33] Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1
    Iain R Hutcheson
    Lindy Goddard
    Denise Barrow
    Richard A McClelland
    Hayley E Francies
    Janice M Knowlden
    Robert I Nicholson
    Julia MW Gee
    Breast Cancer Research, 13
  • [34] CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization
    Werr, Lisa
    Plenker, Dennis
    Dammert, Marcel A.
    Lorenz, Carina
    Bragelmann, Johannes
    Tumbrink, Hannah L.
    Klein, Sebastian
    Schmitt, Anna
    Buttner, Reinhard
    Persigehl, Thorsten
    Shokat, Kevan M.
    Wunderlich, F. Thomas
    Schram, Alison M.
    Peifer, Martin
    Sos, Martin L.
    Reinhardt, H. Christian
    Thomas, Roman K.
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (05) : 821 - 830
  • [35] Stromal Neuregulin-1 (NRG-1) induces ErbB3-mediated resistance to erlotinib therapy in pancreatic cancer
    Liles, J. S.
    Frolov, A.
    Frolova, N. S.
    Frost, A. R.
    Christein, J. D.
    Heslin, M. J.
    Arnoletti, J. P.
    ANNALS OF SURGICAL ONCOLOGY, 2009, 16 : 14 - 14
  • [36] NRG1/ErbB4 and the PI3K/AKT pathway: Novel therapeutic options for schizophrenia
    Law, Amanda J.
    SCHIZOPHRENIA RESEARCH, 2014, 160 (1-3) : E10 - E11
  • [37] Schizophrenia-Relevant, Endophenotypes in Transgenic Mouse Models of NRG1/ErbB4 Hyperstimulation
    Schwab, Markus
    NEUROPSYCHOPHARMACOLOGY, 2015, 40 : S63 - S64
  • [38] Cyclin D1 is induced by heregulin via wild-type ErbB3.
    Kim, M. S.
    JOURNAL OF DENTAL RESEARCH, 2003, 82 : B370 - B370
  • [39] Anti-cancer efficacy of an anti-ErbB3 antibody, ISU104, against the cancers with NRG1-overexpression, NRG1-fusion, or oncogenic ErbB3 mutations
    Hong, Seung-Beom
    Hong, Mirim
    Kim, Tae-Eun
    Kim, Ju Yeon
    Kim, Jung Won
    Cho, Jeongin
    Shin, Bongseok
    Bae, Donggoo
    CANCER RESEARCH, 2020, 80 (16)
  • [40] Alterations in neuregulin1 (NRG1)/ErbB4 signaling are related to specific intracellular signaling pathways in schizophrenia
    Law, Amanda J.
    NEUROPSYCHOPHARMACOLOGY, 2006, 31 : S34 - S34